文献速递儿童消化与营养儿童心血管与肾脏儿童内分泌与遗传代谢

MEK抑制治疗成功缓解伴SOS1突变的Noonan综合征患者的重度淋巴管疾病

Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation.
PubMed 文献 · Pediatrics · 2020-01-01

本文报告一例伴SOS1突变的Noonan综合征患者,出现重度淋巴管异常导致输血依赖的上消化道出血和蛋白丢失性肠病,常规治疗及淋巴介入仅短暂改善。经扩展准入使用MEK抑制剂曲美替尼后,症状缓解,电解质、血红蛋白和白蛋白在3个月内完全正常化,淋巴系统完全重塑。提示对常规治疗失败的RAS通路缺陷合并重度淋巴管疾病患者,抑制RAS-MAPK通路可考虑为治疗选择。

要点

  • Noonan综合征约20%病例合并重度淋巴管疾病,包括乳糜胸和蛋白丢失性肠病。
  • 伴SOS1突变的重度淋巴管疾病患者经曲美替尼治疗后症状缓解、实验室指标正常化。
  • 对常规治疗失败的RAS通路缺陷合并重度淋巴管疾病,MEK抑制可考虑为治疗选项。

核心结论

  • 对RAS通路缺陷合并重度淋巴管疾病且常规治疗失败的患者,抑制RAS-MAPK通路可考虑作为治疗选择,未来可能成为一线治疗。

研究设计与样本

  • 本文为单例病例报告,对象为一名伴SOS1突变的Noonan综合征合并重度淋巴管异常的患者。

主要发现

  • 患者出现输血依赖的上消化道出血和蛋白丢失性肠病,对药物治疗失去反应,多次淋巴介入仅暂时改善症状。
  • 经扩展准入使用曲美替尼后症状缓解,电解质、血红蛋白和白蛋白在用药3个月内完全正常化。
  • 患者淋巴系统出现完全且广泛的重塑,与此前报道的ARAF突变病例相似。

关键数值与推荐

  • 原文提及Noonan综合征约20%的病例与重度淋巴管疾病相关。

临床怎么用

  • 对RAS通路缺陷合并重度淋巴管疾病且常规治疗失败的患者,可考虑MEK抑制作为治疗选项。

局限性

  • 本文为单例病例报告,证据级别有限,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Noonan syndrome is a multiorgan system disorder mediated by genetic defects along the RASknown as RASopathies. It is the second most common syndromic cause of congenital heart disease and, in ∼20% of the cases, is associated with severe lymphatic disorders, including chylothorax and protein-losing enteropathy. Recently, we reported on the use of mitogen-activated protein kinase inhibition in a patient with an ARAF mutation and severe lymphatic disorder leading to an abrupt improvement in symptoms and complete remodeling of the central lymphatic system. Here, we present a patient with Noonan syndrome and severe lymphatic abnormality, leading to transfusion-dependent upper gastrointestinal bleeding and protein-losing enteropathy. The patient stopped responding to medical therapy and underwent several lymphatic interventional procedures, which led only to a temporary improvement in symptoms. Because of a lack of other treatment options, an expanded access approval was obtained, and the patient initiated treatment by mitogen-activated protein kinase inhibition using trametinib. This led to resolution of her symptoms, with complete normalization of her electrolyte levels, hemoglobin, and albumin within 3 months of starting the drug. Similar to the previously reported case, she also had complete and generalized remodeling of her lymphatic system. In patients with RAS pathway defects complicated by a severe lymphatic disorder, inhibition of the RAS-MAPK pathway should be considered as a possible treatment option in patients who failed conventional treatment and might be a first-line treatment in the future.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Dori Y, Smith C, Pinto E, et al. Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation. Pediatrics. 2020. PMID: 33219052. doi:10.1542/peds.2020-0167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。